|Day Low/High||10.48 / 10.68|
|52 Wk Low/High||6.25 / 13.76|
Santa is on his way... A lot of pressure on the jolly fellow this year.
For equity holders in Amarin, now's the time to be implementing my 'Jensen Rules.'
I expect deal volume to have a substantial uptick before the end of 2018 rolls around.
"Despite a voluminous and often fervent literature on "income distribution," the cold fact is that most income is not distributed: It is earned." -- Thomas Sowell Markets are pretty much trading at the same levels as our last update as it looks lik...
On Thursday alone, we experience both free-fall, as well as a raucous rally.
We used to think of what's in the public's interest when it comes to securities.
Warren Buffett continues to eat up Apple's stock. He also has bought a stake in struggling generics drug maker Teva.
The free market is going to take back control of interest rates.
The stock market continues to be under considerable pressure. Here is one thing not to do right now amidst the carnage.
Gains are being left on the table as firms and investors let their politics or social concerns get the better of them.
I'm seeing some weakness in generic-drug stocks -- i.e., Teva Pharmaceuticals , Mylan and Mallinckrodt -- based on a New York Times article that hospitals might move into the generic-drug business.
Teva and Mallinckrodt both lost over 50% of their value in 2017 and might catch some momentum here.
I was out of the office most of the day. To me the most interesting asset class move was in bonds -- with yields down by over five basis points. The 10-year yield fell to under 2.35% though the 2s/10s curve was flat. While municipals rallied in pric...
The broadcast scored an 11.6 metered rating, tops on the night, but short of last week's total.
I missed very little and was better served at my "liquid" lunch meeting. Bitcoin was being bitcoin (+17%) with prices contrasting wildly by Exchanges -- a signpost that volatility will be with this commodity for some time. I have a double dose of Bo...
Some mid afternoon observations: * Small yield flattening in today's session and little change in bond yields. * High yield is slipping a bit. * The U.S. Dollar is strengthening after morning weakness. * Oil down after weeks of strength (-$0.76/ba...
While shoppers were busy looking for bargains at the mall, traders were busy doing the same on Wall Street.
This morning Wells Fargo research describes Teva Pharmaceutical Industries as being "in survival mode." The brokerage expects a 20% reduction in employment (this is broadly anticipated). The company reported in Israel that Teva currently doesn'...
The troubled drug firm slashed its dividend by 75% in August, but its current dividend payout ratio and yield can tell us a lot about the future.
Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.
The Nasdaq (QQQs) turn slightly negative as most of the FANGs reverse lower. Retail, generics (Teva and Mylan ), big pharma (Merck and Bristol-Myers Squibb ) and biotech (Allergan , Gilead Sciences , Celgene ) are conspicuous to the downside. Co...
HSBC has downgraded Teva Pharmaceutical Industries to reduce, lowering its price target from $26 to $6, which automatically disqualifies me from paying attention to the analyst! Seriously, though, the brokerage reduces estimates to reflect likely ...
Wells Fargo has lowered their price target for Teva Pharmaceutical to $12/share after the disappointing third-quarter results and fourth-quarter guidance.
Despite stocks near their all-time records, there are more potholes (this week) than observed on Second Avenue in the Upper East Side in New York City. Today's potholes: * Optical (Oclaro guidedown) * FANG (reaction to earnings) * Retail (again) *...
Looking ahead, Allergan may be more vulnerable than suggested by management or believed by analysts.
My economist side would clearly prefer a rules-based approach toward monetary policy.
There continues to be a lot of interest in Teva Pharmaceutical Industries . I have received a number of additional inquiries via email again over the weekend. Here was my most recent analysis from early October. At the core of my concern is that c...